Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025)
Telix Pharmaceuticals (TLX) reported Non-Current Deferred Tax Liability of $44.7 million for Q4 2025, up 628.73% year-over-year from $6.1 million in Q4 2024, and up 628.73% quarter-over-quarter from $6.1 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Deferred Tax Liability (2024 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $44.7 million in Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $44.7 million, up 628.73% year-over-year; the trailing twelve-month figure through Dec 2025 was $44.7 million (up 628.73% YoY), and the FY2025 annual result was $44.7 million, up 671.33% from the prior year.
- Non-Current Deferred Tax Liability grew to $44.7 million in Q4 2025 per TLX's latest filing, from $6.1 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $44.7 million in Q4 2025 and troughed at $6.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Telix Pharmaceuticals | 4.81 Bn | 4.67 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2025 | 44.71 Mn |
| Dec 31, 2024 | 6.13 Mn |
| Dec 31, 2024 | 6.13 Mn |